BioCentury | Nov 2, 2018
Company News

Synergy evaluating options following slow Trulance uptake

...offers that are significantly higher than those it has already received. This year, Synergy granted Shandong Luoxin Pharmaceutical Group Stock Co. Ltd....
...Business: Gastrointestinal Jaime De Leon Trulance (Brand), SP-304 (Former compound #), guanilib (Former generic), plecanatide (Generic), Trulance (Other) Shandong Luoxin Pharmaceutical Group Stock Co. Ltd. Synergy...
BioCentury | Aug 31, 2018
Financial News

China GL Capital claims 5% stake in U.K.'s Oxford BioDynamics

...about $605 million. That same year, GL Capital, Ally Bridge and Giant Star Global took Shandong Luoxin Pharmaceutical Group Stock Co. Ltd....
BioCentury | Aug 22, 2018
Financial News

China's GL Capital claims 5% stake in U.K.'s Oxford BioDynamics

...about $605 million. That same year, GL Capital, Ally Bridge and Giant Star Global took Shandong Luoxin Pharmaceutical Group Stock Co. Ltd....
...HK$17 per share, or about HK$2.3 billion ($293 million). Elizabeth S. Eaton China Biologic Products Holdings Inc. GL Capital Luoxin Pharmaceutical Oxford...
BioCentury | Aug 10, 2018
Company News

Luoxin gains Chinese rights to Trulance

...Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) granted Shandong Luoxin Pharmaceutical Group Stock Co. Ltd. (Linyi, China) exclusive rights to develop and commercialize gastrointestinal drug...
...Synergy added $0.03 to $1.63 on Aug. 7. Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), New York, N.Y. Shandong Luoxin Pharmaceutical Group Stock Co. Ltd....
...China Business: Gastrointestinal Sandi Wong Trulance (Brand), SP-304 (Former compound #), guanilib (Former generic), plecanatide (Generic), Trulance (Other) Shandong Luoxin Pharmaceutical Group Stock Co. Ltd. Synergy...
BioCentury | Aug 7, 2018
Company News

Luoxin gains Chinese rights to Trulance

...Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) granted Shandong Luoxin Pharmaceutical Group Stock Co. Ltd. (Linyi, China) exclusive rights to develop and commercialize gastrointestinal drug...
...$1.63 on Tuesday. Sandi Wong Trulance (Brand), SP-304 (Former compound #), guanilib (Former generic), plecanatide (Generic), Trulance (Other) Shandong Luoxin Pharmaceutical Group Stock Co. Ltd. Synergy...
BioCentury | Jun 9, 2017
Company News

SciClone going private in $605M deal

...territory. In March, GL Capital, Ally Bridge and Giant Star Global proposed to take private Shandong Luoxin Pharmaceutical Group Stock Co. Ltd....
BioCentury | Jun 8, 2017
Company News

SciClone going private in $605M deal

...territory. In March, GL Capital, Ally Bridge and Giant Star Global proposed to take private Shandong Luoxin Pharmaceutical Group Stock Co. Ltd....
BioCentury | Mar 31, 2017
Company News

Shandong Luoxin Pharmaceutical Group deal

...the remainder. The deal is subject to shareholder approval. Shandong Luoxin Pharmaceutical Group Stock Co. Ltd. (HKSE:8058), Linyi, China Business: Pharmaceuticals Alicia Parker Shandong Luoxin Pharmaceutical Group Stock Co. Ltd....
BioCentury | Mar 27, 2017
Financial News

Giant Star, Ally Bridge in consortium to take Luoxin private

...investor syndicate including Ally Bridge, GL Instrument Investment and Giant Star Global plans to take Shandong Luoxin Pharmaceutical Group Stock Co. Ltd....
...the WuXi transaction in terms of size and impact (see BioCentury, Aug. 15, 2016) . Becky Simon Shandong Luoxin Pharmaceutical Group Stock Co. Ltd....
BioCentury | Jan 6, 2017
Company News

Yuhan, Luoxin deal

...2016 ). Yuhan Corp. (KSE:000100), Seoul, South Korea Shandong Luoxin Pharmaceutical Group Stock Co. Ltd. (HKSE:8058), Linyi, China Business: Cancer Jaime De Leon YH25448 Shandong Luoxin Pharmaceutical Group Stock Co. Ltd. Yuhan...
Items per page:
1 - 10 of 15
BioCentury | Nov 2, 2018
Company News

Synergy evaluating options following slow Trulance uptake

...offers that are significantly higher than those it has already received. This year, Synergy granted Shandong Luoxin Pharmaceutical Group Stock Co. Ltd....
...Business: Gastrointestinal Jaime De Leon Trulance (Brand), SP-304 (Former compound #), guanilib (Former generic), plecanatide (Generic), Trulance (Other) Shandong Luoxin Pharmaceutical Group Stock Co. Ltd. Synergy...
BioCentury | Aug 31, 2018
Financial News

China GL Capital claims 5% stake in U.K.'s Oxford BioDynamics

...about $605 million. That same year, GL Capital, Ally Bridge and Giant Star Global took Shandong Luoxin Pharmaceutical Group Stock Co. Ltd....
BioCentury | Aug 22, 2018
Financial News

China's GL Capital claims 5% stake in U.K.'s Oxford BioDynamics

...about $605 million. That same year, GL Capital, Ally Bridge and Giant Star Global took Shandong Luoxin Pharmaceutical Group Stock Co. Ltd....
...HK$17 per share, or about HK$2.3 billion ($293 million). Elizabeth S. Eaton China Biologic Products Holdings Inc. GL Capital Luoxin Pharmaceutical Oxford...
BioCentury | Aug 10, 2018
Company News

Luoxin gains Chinese rights to Trulance

...Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) granted Shandong Luoxin Pharmaceutical Group Stock Co. Ltd. (Linyi, China) exclusive rights to develop and commercialize gastrointestinal drug...
...Synergy added $0.03 to $1.63 on Aug. 7. Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), New York, N.Y. Shandong Luoxin Pharmaceutical Group Stock Co. Ltd....
...China Business: Gastrointestinal Sandi Wong Trulance (Brand), SP-304 (Former compound #), guanilib (Former generic), plecanatide (Generic), Trulance (Other) Shandong Luoxin Pharmaceutical Group Stock Co. Ltd. Synergy...
BioCentury | Aug 7, 2018
Company News

Luoxin gains Chinese rights to Trulance

...Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) granted Shandong Luoxin Pharmaceutical Group Stock Co. Ltd. (Linyi, China) exclusive rights to develop and commercialize gastrointestinal drug...
...$1.63 on Tuesday. Sandi Wong Trulance (Brand), SP-304 (Former compound #), guanilib (Former generic), plecanatide (Generic), Trulance (Other) Shandong Luoxin Pharmaceutical Group Stock Co. Ltd. Synergy...
BioCentury | Jun 9, 2017
Company News

SciClone going private in $605M deal

...territory. In March, GL Capital, Ally Bridge and Giant Star Global proposed to take private Shandong Luoxin Pharmaceutical Group Stock Co. Ltd....
BioCentury | Jun 8, 2017
Company News

SciClone going private in $605M deal

...territory. In March, GL Capital, Ally Bridge and Giant Star Global proposed to take private Shandong Luoxin Pharmaceutical Group Stock Co. Ltd....
BioCentury | Mar 31, 2017
Company News

Shandong Luoxin Pharmaceutical Group deal

...the remainder. The deal is subject to shareholder approval. Shandong Luoxin Pharmaceutical Group Stock Co. Ltd. (HKSE:8058), Linyi, China Business: Pharmaceuticals Alicia Parker Shandong Luoxin Pharmaceutical Group Stock Co. Ltd....
BioCentury | Mar 27, 2017
Financial News

Giant Star, Ally Bridge in consortium to take Luoxin private

...investor syndicate including Ally Bridge, GL Instrument Investment and Giant Star Global plans to take Shandong Luoxin Pharmaceutical Group Stock Co. Ltd....
...the WuXi transaction in terms of size and impact (see BioCentury, Aug. 15, 2016) . Becky Simon Shandong Luoxin Pharmaceutical Group Stock Co. Ltd....
BioCentury | Jan 6, 2017
Company News

Yuhan, Luoxin deal

...2016 ). Yuhan Corp. (KSE:000100), Seoul, South Korea Shandong Luoxin Pharmaceutical Group Stock Co. Ltd. (HKSE:8058), Linyi, China Business: Cancer Jaime De Leon YH25448 Shandong Luoxin Pharmaceutical Group Stock Co. Ltd. Yuhan...
Items per page:
1 - 10 of 15